Skip to main content

Table 2 Descriptive characteristics of propensity score matched total hip replacement (THR) patients according to red blood cell transfusion within 8 days of surgery.

From: Allogeneic blood transfusion and prognosis following total hip replacement: a population-based follow up study

 

Transfusion n = 2,254

No transfusion n = 2,254

Standardized mean difference***

Age (years)

   

10-49

146 (6.5%)

159 (7.1%)

0.07561

50-59

272 (12.1%)

256 (11.4%)

0.03827

60-69

602 (26.7%)

635 (28.2%)

0.07124

70-79

830 (36.8%)

793 (35.2%)

0.00596

+80

404 (17.9%)

411 (18.2%)

0.18397

Sex

   

Female

1,490 (66.1%)

1,439 (63.8%)

0.11293

Primary hip diagnosis

   

Primary arthrosis

1,647 (73.1%)

1,633 (72.5%)

0.23293

Trauma

323 (14.3%)

319 (14.2%)

0.28662

Other

284 (12.6%)

302 (13.4%)

0.00682

Comorbidity history (yes)

   

Myocardial infarction

104 (4.6%)

113 (5.0%)

0.02865

Congestive heart failure

116 (5.2%)

125 (5.6%)

0.08273

Peripheral vascular disease

97 (4.3%)

95 (4.2%)

0.02495

Cerebrovascular disease

172 (7.6%)

172 (7.6%)

0.11255

Dementia

15 (0.7%)

8 (0.4%)

0.10249

Chronic pulmonary disease

192 (8.5%)

176 (7.8%)

0.06104

Connective tissue disease

169 (7.5%)

161 (7.1%)

0.02309

Peptic ulcer disease

129 (5.7%)

129 (5.7%)

0.07967

Mild liver disease

37 (1.6%)

30 (1.3%)

0.04168

Diabetes (type I and II)

134 (5.9%)

115 (5.1%)

0.05238

Hemiplegia

4 (0.2%)

6 (0.3%)

0.03791

Moderate to severe renal disease

55 (2.4%)

60 (2.7%)

0.06410

Diabetes with end organ damage

61 (2.7%)

47 (2.1%)

0.06301

Any tumor

260 (11.5%)

235 (10.4%)

0.09151

Leukemia

10 (0.4%)

6 (0.3%)

0.04010

Lymphoma

18 (0.8%)

14 (0.6%)

0.04218

Moderate to severe liver disease

11 (0.5%)

12 (0.5%)

0.03710

Metastatic solid tumor

39 (1.7%)

26 (1.2%)

0.08036

Fixation technique

   

Cemented

1,186 (52.6%)

1,175 (52.1%)

0.03568

Cementless

523 (23.2%)

522 (23.2%)

0.05074

Hybrid

545 (24.2%)

557 (24.7%)

0.01191

Type of anesthesia

   

Regional

1,753 (77.8%)

1,757 (78.0%)

0.18378

Duration of surgery (minutes)

   

0-60

418 (18.5%)

426 (18.9%)

0.09806

61-120

1,685 (74.8%)

1671 (74.1%)

0.03567

>121

151 (6.7%)

157 (7.0%)

0.20997

20 hospitals performing the THR procedures*

  

Prophylaxis for heterotopic bone formation **

  

Yes

195 (8.7%)

208 (9.2%)

0.06109

No

2059 (91.4%)

2046 (90.7%)

0.06268

Preoperative Hemoglobin concentration within three months prior to surgery

  

<138.5 g/L

1410 (62.6%)

1362 (60.4%)

0.25041

>138.5 g/L

844 (37.4%)

892 (39.6%)

0.25041

Year of surgery

   

1999

61 (2.7%)

58 (2.6%

0.03572

2000

60 (2.7%)

56 (2.5%)

0.06520

2001

94 (4.2%)

93 (4.1%)

0.02234

2002

309 (13.7%)

333 (14.8%)

0.02030

2003

239 (10.6%)

254 (11.3%

0.00876

2004

377 (16.7%)

392 (17.4%)

0.04756

2005

347 (15.4%)

333 (14.8%)

0.01024

2006

435 (19.3%)

411 (18.2%)

0.01185

2007

332 (14.7%)

324 (14.4%)

0.00976

  1. Data are shown in number (%) unless otherwise specified. *Good balance between groups for each of the 20 hospitals included in the propensity score was achieved in general. ** Anti -rheumatic drugs were used as prophylaxis for heterotopic bone formation. *** A standardized mean difference that exceeds 0.1 is indicative of significant imbalance between groups.